Forty-seven patients with mild hypertension and 48 normotensive patients entered a blinded, parallel study in which they received a placebo, 10 mmol/day calcium carbonate (CaCO 3 ), or 20 mmol/day CaCO 3 . There were no significant differences in blood pressure changes among the groups. In the hypertensive group and in patients with the highest blood pressure there were individual falls in systolic pressure, particularly in the group receiving 10 mmol daily A number of studies investigating the effect of calcium supplementation on blood pressure in humans have now been performed, and results are conflicting.
pidemiological evidence links low dietary intakes of calcium with increased blood pressure, '-4 and animal studies suggest a role for calcium in the development of hypertension in some strains of rats with genetic hypertension. 5 -7 A number of studies investigating the effect of calcium supplementation on blood pressure in humans have now been performed, and results are conflicting. 8 - 30 Our present study was undertaken in normotensive and hypertensive subjects. After a preliminary period, subjects were randomized to placebo or to two levels of calcium carbonate (CaCO 3 ) supplementation (10 and 20 mmol/day), and blood pressures were followed for 2 months. At the end of the study a number of patients classified as responders were, after at least 3 months, rerandomized to placebo or CaCO 3 (20 mmol/day), and we made a preliminary report. 31 
Subjects and Methods
Patients who entered the study were male or female between the ages of 22 and 77 years. Subjects were recruited from a screening program conducted among staff at the hospital and a local educational institute. A number of hypertensive subjects had previously participated in a dietary study of the effect of alterations in sodium and potassium intake on blood pressure. 3233 At least 1 month elapsed from the end of that study before patients entered the present study.
Patients were classified as hypertensive if their average diastolic blood pressure was greater than 90 mm Hg over three visits 14 days apart. Patients previously in the diet intervention study were all classified as hypertensive, even if during the preliminary period to the present study their diastolic blood pressure was less than 90 mm Hg. We recognized the potential difficulty caused by this and in the protocol was the proposition to reclassify all patients as normotensive and hypertensive based on the mean arterial pressure at randomization (:£ 105 mm Hg normotensive, >105 mm Hg hypertensive).
All patients completed three preliminary visits 2 weeks apart immediately before randomization. Forty-seven hypertensive (41 men, six women) and 48 normotensive subjects (28 men, 20 women) were randomly assigned to receive placebo, CaCO 3 (10 mmol/day), or CaCO 3 (20 mmol/day). Subjects and nursing staff involved in blood pressure measurements were blinded to the supplementation.
After randomization subjects were seen 1 and 2 months later. At each visit patients returned a 24-hour urine collection. Patients were weighed and after sitting for 5 minutes had their blood pressure taken in triplicate with a Dinamap automated sphygmomanometer (Criticon Inc., Tampa, Florida). The first value was discarded, and the mean of the last two readings used. Blood was taken for biochemical analysis twice during baseline measurement and twice during the supplementation period. Subjects provided the dietitian with a 24-hour dietary recall coinciding with the day of their urine collection. Capsule count was performed to determine compliance.
At the end of the study patients were classified before analysis into a number of groups (see below) to determine the response of different groups to CaCO 3 . One classification was responders and nonresponders. Thirty patients from the study were classified as responders, and 12 of these (eight men, four women; three normotensive, nine hypertensive) entered a subsequent study. Patients were removed from supplements for at least 3 months. Patients had two preliminary visits 14 days apart and were then randomized to placebo or to CaCO 3 (20 mmol/day). They were seen 4, 6, and 8 weeks later and measurements similar to those of the first study were made. After completion of this phase, four subjects crossed over to the other medication and were followed for another 8 weeks.
Biochemical Analysis
Blood samples were taken with minimum stasis on two occasions during baseline and intervention phases. Plasma was analyzed for sodium, potassium, chloride, carbon dioxide, urea, creatinine, protein, albumin, alkaline phosphatase, y-glutamyl transferase, calcium, phosphate, magnesium, cholesterol, and plasma renin concentration. Plasma renin concentration was measured by radioimmunoassay 34 on frozen samples stored at -20° C. Ionized calcium was calculated. 35 In the rechallenge study, ionized calcium was determined directly on serum, within 2 hours of sampling, by a Copenhagen radiometer, adjusted for blood pH. Plasma renin activity was determined with a radioimmunoassay on frozen samples. 36 Twenty-four-hour urine collections were made in both studies and analyzed for sodium, potassium, calcium, magnesium, phosphate, chloride, urea, and creatinine. Samples were treated with hydrochloric acid for 24 hours after collection to dissolve any precipitate. In the rechallenge study, urine was collected into bottles containing hydrochloric acid to prevent precipitation of calcium salts.
Dietary Analysis
Three 24-hour dietary histories were taken and analyzed for protein, fat, carbohydrate, energy, sodium, potassium, calcium, magnesium, and alcohol. Dietary analysis was performed with a computer program based on the composition of foods by McCance and Widdowson 37 (British Food Tables) with appropriate adjustments for the addition of Australian foods.
Analysis of Data
All subjects returning for one visit postintervention were included. Values after 4-week intervention were substituted for the values at 8 weeks for the three patients who did not complete the study. The effect of intervention was determined by comparing the last baseline blood pressure measurement with the last intervention measurement and also by comparing all values in the preliminary visits with all values in the trial phase. Paired and unpaired / tests were used as well as analysis of variance and univariate analysis. 38 - 39 Data was analyzed by means of SPSSX Statistical Package for Social Sciences computer statistical analysis. The power of the study to detect a fall of 5 mm Hg was 95% in the normotensive and hypertensive group and overall. There was a power of 90% in the various reclassified grouping. A number of subgroup analyses have been done. Conclusions made by subgroup analysis are unreliable and may be inaccurate. However, as conclusions in similar studies have been made principally from such analysis, they have been performed to attempt to verify conclusions made from subgroup analysis.
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Subclassification
Responders and nonresponders. Two arbitrary classifications were made. The first required responders to have a fall in systolic blood pressure of 15 mm Hg or more. We used this classification to determine if these persons differed from others in that group in baseline characteristics. The second classification required subjects in the hypertensive group to have a fall greater than or equal to 10 mm Hg in systolic blood pressure and for subjects in the normotensive group to have a fall greater than or equal to 5 mm Hg. We used this classification to identify which patients to enter into rechallenge study.
Hypertension at time of allocation. This was based on mean arterial pressure at the time of randomizatipn by using criteria similar to those of McCarron and Morris. 17 If mean arterial pressure was greater than 105 mm Hg, patients were classified as hypertensive.
Sodium intake. Normotensive and hypertensive patients were divided separately into equal-sized high-, middle-, and low-sodium groups.
Renin subdivision. Normotensive and hypertensive patients were divided separately into equalsized high-, middle-, and low-renin groups based on their plasma renin concentration measured during the baseline period. To allow for the effect of sodium intake on plasma renin, the plasma renin concentration was multiplied by 24-hour urine sodium measured the previous day, and a similar subdivision was then made.
The purpose of dividing patients into three groups was predominantly to obtain a high-, a medium-, and a low-renin group for comparison. It was recognized that similar information may be obtained by regression analysis, but we chose our procedure as it may help identify threshold effect. A full listing of the correlations and comparisons made is available from the authors. In this article we present only the positive and more relevant negative findings.
Results
Forty-seven hypertensive and 48 normotensive subjects entered the study. Three hypertensive subjects completed only 4 weeks of therapy. All other subjects completed the study. Compliance assessed by capsule count indicated that 93% took 80% or more of their capsules, 5% took between 55% and 80%, and 2% took less than 55%. When subdivided according to mean arterial pressure equal to or greater than 105 mm Hg, there were 29 people in the hypertensive group and 66 in the normotensive group.
Baseline Values
The baseline characteristics of the hypertensive and normotensive groups before randomization are listed in Table 1 . There were some minor differences between the two groups. The hypertensive group was older and included more men. The group had a higher body weight; a lower dietary intake of calcium; a higher intake of alcohol; a higher plasma creatinine, calculated ionized calcium, and cholesterol; and a greater 24-hour urinary creatinine excretion. The 24-hour urinary potassium excretion was greater in the hypertensive group but was similar when divided by 24-hour creatinine. Plasma renin concentration was higher in the normotensive than in the hypertensive group, but this was not significant.
When subjects were reclassified on the basis of mean arterial pressure, comparisons between the normotensive and hypertensive groups were similar to the above (Table 1) .
In normotensive and hypertensive groups there were no differences between the groups allocated to capsules of placebo, calcium carbonate (10 mmol/ day), or calcium carbonate (20 mmol/day).
Response of Blood Pressure to Placebo or Calcium Carbonate Supplementation
The systolic and diastolic blood pressures at the four visits are summarized in Figure 1 . There were no significant falls in blood pressure in any study group. In the hypertensive and the reclassified hypertensive group supplemented with 10 mmol/ day CaCO 3 , there were occasional differences in systolic blood pressure that approached significance. There was no difference between the pressure drop of the placebo group and that of either CaCO 3 group. In the normotensive group, blood pressure did not alter significantly. A variety of statistical techniques, including analysis of variance, paired t test, and nonparametric tests revealed no significance in blood pressure changes of any group. Pulse rate or body weight did not alter significantly. Plasma biochemical values in general showed no alterations, but there were small changes in plasma calcium and magnesium, which reached significance particularly for calculated ionized calcium (Table 2 ). Other variables not listed did not differ from their baseline values.
In the normotensive group calcium excretion increased in persons given 10 and 20 mmol/day (Table 3) ; in the hypertensive group it appeared to increase in all three groups, but the increase in the group given 20 mmol/day was greater than in the . 13 .20t
. 12 .18t
. 13 .20t 
Individual Responses in Blood Pressure
Individual blood pressure responses to placebo and to the two levels of calcium supplementation are shown in Figure 2 . More people in the hypertensive groups given CaCO 3 had a fall in systolic blood pressure greater than 15 mm Hg (6 of 30) than in the placebo group (0/17, x 2 test p<0.05). The characteristics of this group of patients were compared with those of patients in the hypertensive group who were given calcium supplementation but had no fall in blood pressure (Table 4) . Comparisons have been made similar to those in Table 1 , and those not listed did not differ. Linear correlations were made between the change in systolic or diastolic blood pressure and an initial variable or a change in that variable. Many such comparisons were made by univariate analysis. These used either the blood pressure at the end of the study or the blood pressure at both postintervention visits compared with baseline. The results did not differ. The fall in systolic blood pressure correlated with baseline systolic blood pressure. The fall in diastolic blood pressure correlated with baseline plasma bicarbonate level. There were no correlations with other baseline variables.
There were a number of significant but weak correlations between changes in systolic and diastolic blood pressure and changes in urinary electrolytes. Selected correlation coefficients and their significance are listed in Table 5 . No other comparisons made reached significance.
Subgroup Analysis
Subjects were divided according to their baseline 24-hour urine sodium into three groups, low, medium, and high, to determine if this predicted the response to calcium carbonate. Patients were also subdivided into three renin groups and also into three groups based on their renin multiplied by 24-hour urine sodium.
The response in systolic and diastolic blood pressure in these groups is indicated in Table 6 , where data for the hypertensive group is indicated. There were no significant alterations in normotensive subjects. Table 6 data confirm the conclusion made from univariate analysis, that response to CaCO 3 is not determined by the initial 24-hour urinary sodium excretion or by plasma renin concentration. Likewise, the subdivision into normal, low, and high renin with correction for urine sodium did not determine who would respond.
Rechallenge Study
Twelve of the 30 apparent responders were randomized into a repeat study, and they received 
0.002
Values are mean±SEM; p by paired I test. There were no differences in any other variables measured that were the same as in Table 1. placebo or 20 mmol/day CaCO 3 . Four subjects received placebo and CaCO 3 in a crossover design. Details of the subjects and their previous responses are provided in Table 7 . One person received placebo in the first study and placebo in the rechallenge. He had a fall in systolic blood pressure of 12 in the first study and 17 with rechallenge. However, he has not been included in the analysis as he contributed little to the evaluation of the proposition.
In subjects given placebo in the rechallenge study, the change in blood pressure was 0±4/3±3 mm Hg compared with a change of -19±3/-8±4 mm Hg in the initial study when given 10 or 20 mmol/day CaCO 3 . In subjects given 20 mmol/day CaCO 3 in the rechallenge study, the change in blood pressure was l±5/0±4 mm Hg compared with a change of 14±2/ -4±3 mm Hg in the initial study. The change in blood pressure was not different from zero with either CaCO 3 or placebo. Three of the seven patients who had previously "responded" to CaCO 3 had a rise in blood pressure, while four still had a change in the same direction. Three of the eight patients given placebo had a fall in blood pressure similar to that observed when they were given CaCO 3 .
Discussion
Calcium supplementation for 8 weeks had no significant effect on blood pressure in either normotensive or hypertensive individuals. In hypertensive individuals given 10 mmol CaCO 3 /day, there Values are mean±SEM. CaCOj group pooled. Some patients deleted due to unreliable urine collection or lack of value. (-) indicates a rise in blood pressure. *p<0.05.
TABLE 5. Changes Blood Pressure Correlated With Initial Urinary Electrolytes and Changes in Urinary Electrolytes
Variables compared
With initial values
was a fall of 7 mm Hg systolic and 2 mm Hg diastolic at 8 weeks. This fall was not significant and was not present at 4 weeks. In people given 20 mmol CaCO 3 there was no fall, and in the placebo group the fall in blood pressure was 3/2 mm Hg. Thus the maximum possible fall compared with placebo control was 4 mm Hg systolic with no change in diastolic blood pressure. In normotensive patients there was no significant effect on blood pressure of either dose of CaCO 3 , and the fall in the two calcium-supplemented groups combined was 1.4/0.8 mm Hg compared with 0.5/1.4 mm Hg in the placebo group, changes that were not significantly different from baseline or from each other.
The present study conflicts with those claiming calcium supplementation reduces blood pressure in persons with mild hypertension. 8 -20 However, this study is compatible with those reporting that calcium supplementation does not reduce blood pressure. 21 -30 The difference from the positive studies is more in the claims of the authors than in results. Thus in a study by McCarron and Morris, 17 the subjects' blood pressure changed by -6 / -2 in an erect position and -3/0 in a supine position in the calcium-supplemented group and by 1.0/0 in an erect position and 0/0 in a supine position in the placebo group. The changes that were significantly different from placebo were in the erect-position blood pressure and a fall of 3 mm Hg in supineposition systolic pressure. Subsequently the same authors reported two other studies. 18 -19 In one 18 they selected patients whom they had predicted would have the greatest fall in blood pressure. The only significant fall was in the erect-position systolic blood pressure (4+2 mm Hg). The fall in the placebo group was 2+2 mm Hg; the change in the intervention group, although different from its baseline value, was not different from the change in the placebo group. In a subsequent study 19 of 60 patients with mild hypertension, blood pressure failed to drop significantly when these patients were compared with those receiving placebo. A group of patients has been selected as responders and followed for 2 years to determine the continuing effect of calcium supplementation. However, this group has not been rechallenged, and this fall may be a selection artifact. Thus the data from the present study are in general agreement with that of McCarron and Morris, but the conclusions drawn are opposed. 17 In another reportedly positive study, Grobbee et al" found a significant fall in diastolic blood pressure of 3 mm Hg at 6 weeks, but at 12 weeks the fall was 2 mm Hg and not significant. Other studies have found effects on systolic but not on diastolic blood pressure 121427 ; effects on diastolic but not on systolic blood pressure 811 ; falls in systolic blood pressure and rises in diastolic blood pressure 13 ; effects on supine-position but not erect-position blood pressure 14 ; and effects on erect-position but not supine-position blood pressure. 17 All studies quoted have been of at least 4 weeks duration, and the patients have received at least 10 mmol/day of calcium, which would have elevated their calcium into the recommended daily allowance. The marked variability in response causes concern as to whether changes were due to calcium supplementation or to factors not accounted for in the protocol or were a statistical quirk caused by spontaneous blood pressure variations.
If there were a small overall drop in blood pressure, there might be a specific group of people who would respond to calcium supplementation. The most logical group from epidemiological studies would be those on a low dietary intake of calcium. It should be noted that in this study most patients were receiving the recommended daily intake of calcium, which is at variance from some studies in black people. However, in this and other intervention studies there has been no correlation between response and initial calcium intake, and a correlation was not observed in an intervention study in which subjects adhered to a low calcium diet while taking calcium supplements. 29 In the six hypertensive patients who had the greatest falls in systolic blood pressure with calcium supplementation, there were some minor differences from the "nonresponders." There was a trend for 24-hour urine sodium and the sodium: potassium ratio to be greater in the responders; for ionized calcium, 24-hour urine potassium and phosphate tended to be less. However, this is subset analysis. Even if the trend were significant, it would not prove that this was a predictive difference. Dietary history and assessment showed that responders had a higher sodium: potassium ratio in their food intake.
Lyle et al 40 reported that responders were older, had a higher baseline mean arterial pressure, a lower serum calcium, and higher parathyroid hormone levels. These observations are not supported by the present study. Subgroup analysis in other studies have suggested that responders tend to be female, 17 have increased body weight, 11 higher levels of parathyroid hormone, 11 lower levels of ionized calcium, 41 lower plasma renin levels, 41 elevated 1,25-dihydroxycholecalciferol, 41 and increased urinary calcium excretion. 27 The lack of consistency in identifying markers for response to calcium supplementation among studies indicates caution in interpretation of results from subgroup analysis. An association between response and parathyroid hormone levels has been reported in at least two studies.
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It has been proposed that those most likely to respond to calcium supplementation will have either a low 17 or a high 40 sodium intake. Resnick's view 41 is more complicated as it also relates to renin responsiveness. It is claimed that calcium protects from the blood pressure-raising effect of sodium.
-43
If this were true, it could explain the lack of response in this study, as some people in the hypertensive group were on a reduced sodium intake. However, when the hypertensive and normotensive groups were subdivided according to their sodium intake, no one group responded more than another. In fact, the group on the lowest sodium intake tended to have the greatest fall in blood pressure. Univariate analysis showed no correlation between the fall in diastolic or systolic blood pressure and 24-hour urinary sodium excretion (whether factored by creatinine or not).
The other variable reported to influence the response to calcium is plasma renin or more correctly the renin classification of a patient by the method of Brunner et al. 44 We have not been able to observe such a relation 45 in a cross-sectional study of a population. Thus we have been unable to classify subjects in this fashion. In the present study, by univariate analysis there were no correlations between baseline plasma renin concentration (or plasma renin concentrate x urine sodium) and the change in systolic or diastolic blood pressure, or between the change in plasma renin concentration and the change in systolic or diastolic blood pressure.
If a group of patients exist who respond to calcium, it should be possible to identify and enter them into a double-blind study comparing CaCOj with a placebo and to obtain a clear and predictable response. The results from such studies have been no better than results in randomly selected hypertensive patients. 121819 The second approach is to identify apparent responders and restudy them as before, allocating half to placebo and half to CaCO 3 . This approach was used in this study, and placebo and CaCO 3 caused similar blood pressure changes. The rechallenge indicated that there was no conclusive evidence for a response in any patient, and the almost identical overall absence of response to placebo or to CaCO 3 in these people who had previously responded indicates that the responders may have been at one end of the distribution curve of random variation.
It cannot be stated that calcium intake does not alter blood pressure in some persons. However, if calcium lowers blood pressure in a significant number of people, there must also be a rise in blood pressure in some, as the overall fall, if present, is small. Thus it is difficult to accept the advice that calcium intake should be increased to prevent hypertension. Alternatively, calcium supplementation may reduce blood pressure in a small group of people; however, at present it does not appear possible to predict in whom.
